Nkarta, Inc.
Clinical trials sponsored by Nkarta, Inc., explained in plain language.
-
Immune cell therapy targets autoimmune diseases in early trial
Disease control Recruiting nowThis study tests a new treatment called NKX019, made from immune cells (natural killer cells) that are engineered to target and destroy certain immune cells causing disease. It is for people with autoimmune conditions like systemic sclerosis, inflammatory myopathies, or vasculiti…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 26, 2026 08:38 UTC
-
Immune cell therapy takes on lupus kidney disease
Disease control Recruiting nowThis study tests a new treatment called NKX019, which uses specially engineered immune cells (CAR NK cells) to target and calm overactive immune cells that attack the kidneys. It is for people with active lupus nephritis or primary membranous nephropathy who have not responded to…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC